Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223873 | 0.91 | PTPN1 (0.41) | PTPN1ADRB2ADRB1DRD2ADRA1D | |
| SCHEMBL3209496 | 0.90 | PTPN1 (0.48) | PTPN1ADRB2ADRB1DRD2ADRA1D | |
| SCHEMBL3215342 | 0.88 | KDM4E (0.46) | PTPN1ADRB2ADRB1DRD2ADRA1D | |
| SCHEMBL3205368 | 0.82 | PTPN1 (0.53) | PTPN1PTPN2KDM4EHDAC1HDAC8 | |
| SCHEMBL4449820 | 0.76 | ADRB2 (0.36) | ADRB2ADRB1DRD2ADRA1DKDM4E | |
| SCHEMBL2937127 | 0.76 | PTPN1 (0.47) | PTPN1PTPN2 | |
| SCHEMBL2933529 | 0.74 | KDM4E (0.47) | ADRB2ADRB1DRD2ADRA1DKDM4E | |
| SCHEMBL2935327 | 0.72 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL27733152 | 0.71 | KDM4E (0.41) | ADRB2ADRB1DRD2ADRA1DKDM4E | |
| SCHEMBL3216168 | 0.70 | PTPN1 (0.48) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| EP-2227245-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| WO-2009068689-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | PTPN1 10/4885ADRB2 1983/4885ADRB1 1589/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885ADRB2 4290/4885ADRB1 3772/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885ADRB2 2381/4885ADRB1 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.